Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

2 Stocks That Could Surprise Investors in 2023

The healthcare industry can make for a safe place to invest regardless of the macroeconomic conditions. A couple of healthcare stocks that are diversified and that could be good buys heading into the new year are AstraZeneca (NASDAQ: AZN) and PetMed Express (NASDAQ: PETS). AstraZeneca's business performed well in 2022, but its stock isn't doing as well as perhaps it should be.

Why Shares of Compugen Rose 16.5% on Wednesday

Shares of Compugen (NASDAQ: CGEN), a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday. The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and closing at $1.20. The stock has been volatile, with a 52-week low of $0.51 and a 52-week high of $4.88.

Mirati Therapeutics: Is There A Big Pharma Buyout In Play And What's The Price Tag?

Mirati Therapeutics will find out in December if the FDA will approve its lead drug candidate Adagrasib in NSCLC. Read why the company also is part of acquisition speculation.

AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell receptor therapies.

AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022

WILMINGTON, Del., November 30, 2022--AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.

ADC Therapeutics: Running Through A Stretch Of Bad Luck

ADC Therapeutics faced the brunt of the FDA's new policy against rampant accelerated approvals. See why ADCT stock remains something of a risky bet.

UPDATE 2-AstraZeneca boosts cancer portfolio with $320 mln Neogene deal

AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead. "Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research.

AstraZeneca acquires biotech Neogene for $320M in bid to expand cancer treatments

By Scott Kanowsky

BOE: Global Exposure, Call Writing Strategy, ~7.6% Distribution Yield

BlackRock Enhanced Global Dividend Trust's discount is attractive and leads to an enticing distribution yield. See the factors that make BOE CEF a Buy.